Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029184 | 0.89 | ACHE (0.33) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL15580970 | 0.89 | PDE4B (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10029183 | 0.89 | ACHE (0.33) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029176 | 0.88 | PDE4B (0.38) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029173 | 0.88 | PDE4B (0.38) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL15580966 | 0.84 | PDE4B (0.43) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15580957 | 0.83 | PDE4B (0.47) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL15580954 | 0.83 | SLC6A2 (0.31) | ACHECA1CA2 | |
| SCHEMBL10029179 | 0.82 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL701629 | 0.82 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434689-B2 | Processes for the preparation of isoindole compounds and isotopologues thereof | CELGENE CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | AMGEN INC. | 2015-07-02 | — | — | US | disclosed |
| US-8981117-B2 | Processes for the preparation of isoindole compounds and isotopologues thereof | CELGENE CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140081032-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | CELGENE CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | HPD, DHPS, IDH2 | ACHE 1028/4885CA1 1306/4885CA2 1911/4885 |
| US-20140081032-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | HPD, DHPS, IDH2 | ACHE 1028/4885CA1 1306/4885CA2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.